1. An increased incidence of new cardiovascular disease was seen in individuals with autoimmune disease compared to those without. 2. ...
1. Olokizumab was superior to placebo in improving rheumatoid arthritis (RA) symptoms. 2. Olokizumab was also noninferior to adalimumab in ...
1. Compared to placebo, methotrexate did not significantly reduce the risk of the development of clinical arthritis in at-risk patients. ...
1. Patients with rheumatoid arthritis (RA) treated with tofacitinib showed a higher risk of developing major adverse cardiovascular events and ...
1. This retrospective cohort study found that patients with immune dysfunction experienced a reduction in COVID-19 infection incidence after full ...
1. Among a large, matched cohort of veterans with rheumatoid arthritis, initiation of hydroxychloroquine was not associated with a higher ...
1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab. ...
1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab. ...
1. Upadacitinib was superior to abatacept in achieving remission at 12 weeks for patients with rheumatoid arthritis refractory to biologic ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.